Santos da Silva Jorge

CEO Santos da Silva Jorge sold 150,000 MLTX shares in 2 transactions (April 10–13, 2026) for $2.75M at blended $18.35, reducing stake 4.9% amid unprofitable operations.

Santos da Silva Jorge, CEO of MoonLake Immunotherapeutics, executed 2 separate sales totaling 150,000 shares for $2,752,162.86 at an average price of $18.35 per share. The company posted a net loss of $69,729,000 in its most recent full fiscal year, and the stock trades at $18.78 current price—down 69.7% from its 52-week high of $61.99. His prior sales at MLTX show mixed timing: 3 of 5 prior sells were well-timed at the 90-day mark, but his two most recent MLTX sales (December 2025) showed divergent outcomes, with 90-day returns of +26.4% and +20.4% respectively, indicating those recent sales were not well-timed. The current sale reduces his post-transaction holdings to 2,924,893 shares from 3,074,893 shares, retaining a substantial stake despite the disposal.

CEO Jorge sells 200,000 shares for $2,974,700.00; prior 5 MLTX trades all declined 90d post-sale; stock down 76.4% from 52-week high.

Santos da Silva Jorge (Chief Executive Officer) executed 2 separate sales totaling 200,000 shares for $2,974,700.00 on 2025-12-08 and 2025-12-09, reducing his holdings from 3,078,577 shares to 2,878,577 shares (-6.5%). This transaction occurs while MoonLake's stock has fallen 73.1% over 90 days and 76.4% from its 52-week high of $61.99, trading at $14.61 (current). The CEO's timing pattern is stark: across his 5 prior sales at MLTX, all were followed by 90-day declines ranging from 24.2% to 32.7%, establishing a 100% accuracy rate at timing exits before further deterioration. The company remains unprofitable, with net income of $-69,729,000.00 over its most recent fiscal year. Combined with the stock's extreme recent weakness and the CEO's consistent track record of exiting MLTX before subsequent 90-day losses, this sale warrants scrutiny of whether near-term catalysts may pose further downside risk.